Overview

Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the effectiveness and safety of atomoxetine in enhancing attention and concentration among childhood survivors of cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Temple University
Collaborator:
Eli Lilly and Company
Treatments:
Atomoxetine Hydrochloride